|
Orthologous residues
|
|
STF‑1 (human): S203‑p, STF‑1 (mouse): S203‑p, STF‑1 (rat): S203‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phosphoamino acid analysis, phosphopeptide mapping
|
|
Disease tissue studied:
breast cancer, gestational cancer, gestational trophoblastic choriocarcinoma
|
|
Relevant cell lines - cell types - tissues:
COS (fibroblast), JEG-3 (uterine), MCF-7 (breast cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, monkey
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK2 (human)
|
activation of upstream enzyme, modification site within consensus motif, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
|
|
c-Raf (human)
|
|
increase
|
constitutively active
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation, molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
GRIP1 (human)
|
|
Induces
|
|
|
mammalian two-hybrid, pull-down assay
|
|
SMRT (human)
|
|
Induces
|
|
|
mammalian two-hybrid, pull-down assay
|
|
